Biogen Total Assets 2010-2022 | BIIB

Biogen total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Biogen total assets for the quarter ending March 31, 2022 were $23.614B, a 1.01% decline year-over-year.
  • Biogen total assets for 2021 were $23.877B, a 3.01% decline from 2020.
  • Biogen total assets for 2020 were $24.619B, a 9.6% decline from 2019.
  • Biogen total assets for 2019 were $27.234B, a 7.69% increase from 2018.
Biogen Annual Total Assets
(Millions of US $)
2021 $23,877
2020 $24,619
2019 $27,234
2018 $25,289
2017 $23,653
2016 $22,877
2015 $19,505
2014 $14,315
2013 $11,863
2012 $10,130
2011 $9,050
2010 $8,092
2009 $8,552
Biogen Quarterly Total Assets
(Millions of US $)
2022-03-31 $23,614
2021-12-31 $23,877
2021-09-30 $23,807
2021-06-30 $24,470
2021-03-31 $23,855
2020-12-31 $24,619
2020-09-30 $24,934
2020-06-30 $25,512
2020-03-31 $26,119
2019-12-31 $27,234
2019-09-30 $27,484
2019-06-30 $26,288
2019-03-31 $26,446
2018-12-31 $25,289
2018-09-30 $25,492
2018-06-30 $23,953
2018-03-31 $26,090
2017-12-31 $23,653
2017-09-30 $23,073
2017-06-30 $21,759
2017-03-31 $21,196
2016-12-31 $22,877
2016-09-30 $22,105
2016-06-30 $21,515
2016-03-31 $20,675
2015-12-31 $19,505
2015-09-30 $20,728
2015-06-30 $16,759
2015-03-31 $15,219
2014-12-31 $14,315
2014-09-30 $13,704
2014-06-30 $12,918
2014-03-31 $12,230
2013-12-31 $11,863
2013-09-30 $11,250
2013-06-30 $10,842
2013-03-31 $10,165
2012-12-31 $10,130
2012-09-30 $9,631
2012-06-30 $9,162
2012-03-31 $9,114
2011-12-31 $9,050
2011-09-30 $8,802
2011-06-30 $8,622
2011-03-31 $8,294
2010-12-31 $8,092
2010-09-30 $7,394
2010-06-30 $7,502
2010-03-31 $8,217
2009-12-31 $8,552
2009-09-30 $9,026
2009-06-30 $8,777
2009-03-31 $8,575
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $28.662B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00